A study of Ceftolozane/tazobactam in patients with extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) infections

Trial Profile

A study of Ceftolozane/tazobactam in patients with extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) infections

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Pseudomonal infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Apr 2018 New trial record
    • 28 Mar 2018 Results published in the Infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top